PHARMACEUTICAL USE OF HYPOXIA-INDUCIBLE LIPID DROPLET-ASSOCIATED PROTEIN OR TRUNCATED FRAGMENT THEREOF

The present invention relates to the field of biomedicine, and relates to a pharmaceutical use of a hypoxia-inducible lipid droplet-associated protein or a truncated fragment thereof. Specifically, the present invention relates to a use of a hypoxia-inducible lipid droplet-associated protein or a truncated active fragment thereof in the preparation of a drug for treating or preventing hyperlipidemia, hyperlipidemia complications or neurodegenerative diseases, or a use of the hypoxia-inducible lipid droplet-associated protein or the truncated active fragment thereof in the preparation of a drug for reducing the apolipoprotein level, low-density lipoprotein level, or very low-density lipoprotein level in blood or cerebrospinal fluid..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 13. März Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

ZOU YILONG [VerfasserIn]
SHI TAOTAO [VerfasserIn]
WU TIANSHU [VerfasserIn]
WANG FENGXIANG [VerfasserIn]
LU YANG [VerfasserIn]
PAN ZIJIAN [VerfasserIn]
HAN JINGRONG [VerfasserIn]
PENG QIN [VerfasserIn]
WANG YIXIN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-03-13, Last update posted on www.tib.eu: 2024-04-23, Last updated: 2024-04-26

Patentnummer:

EP4335453

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA001318780